Serina Therapeutics, Inc. (SER) Form 10-Q — May 14, 2026
Serina Therapeutics reported a net loss of $6.9 million for the first quarter of 2026, driven by $3.2 million in R&D expenses and $3.1 million in general and administrative costs. The company raised $21.2 million in gross proceeds through a private placement (PIPE) led by Board member Dr. Gregory Bailey, which included the issuance of common stock, pre-funded warrants, and redeemable warrants. Despite the capital raise, management disclosed substantial doubt about the company’s ability to continue as a going concern.
Key figures
- Total Debt
- 3010000
- Cash Position
- 24526000
- Gross Proceeds
- 21200000
- Shares Outstanding
- 14997505
- Ga Expenses
- 3100000
- Rd Expenses
- 3200000
Price after filing
Close on the filing date to close N calendar days later (from $1.72). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.